# Andrew Quong

> Andrew Quong is President and CEO of InterVenn Biosciences, a South San Francisco-based precision diagnostics company unlocking the human glycoproteome through AI-powered platforms. With a PhD in Physics and over 30 years spanning national laboratories, academia, and biotech, Quong bridges the physical and computational sciences with clinical medicine. He led InterVenn's development of GlycoKnow Ovarian, a non-invasive blood-based liquid biopsy test for distinguishing ovarian cancer from benign masses, and has steered the company through key commercialization milestones including a $201M Series C raise in 2021.

- **Role:** President and CEO at InterVenn Biosciences
- **Organizations:** InterVenn Biosciences, Standard BioTools (formerly Fluidigm), Frederick National Laboratory for Cancer Research, Thomas Jefferson University, Georgetown University, Lawrence Livermore National Laboratory, Sandia National Laboratories, Naval Research Laboratory
- **Nationality:** American
- **Education:** B.A. in Physics and Applied Mathematics, University of California, Berkeley, Ph.D. in Physics, University of California, Irvine, Postdoctoral Fellowship (National Research Council Fellow), Naval Research Laboratory
- **Known for:** Led InterVenn Biosciences through its $201 million Series C fundraise in August 2021, Oversaw development and commercialization of GlycoKnow Ovarian, a proprietary blood-based non-invasive ovarian cancer diagnostic, Secured AMA PLA code for GlycoKnow Ovarian in 2025, enabling wider clinical integration

## Career timeline

- **~1993-1998** — Senior Member of Technical Staff at Sandia National Laboratories
- **1998-2000** — Staff Scientist at Lawrence Livermore National Laboratory (LLNL)
- **2001-2004** — Group Leader, Computational Systems Biology and Computational Materials Science at LLNL
- **2004-2005** — Faculty, Department of Oncology, Georgetown University
- **2006-2013** — Associate Professor, Department of Cancer Biology, Thomas Jefferson University
- **2013-2019** — Director of Strategic Scientific Initiatives and Partnerships, Frederick National Laboratory for Cancer Research
- **2019-2022** — Chief Scientific Officer and Microfluidics Franchise Leader at Fluidigm Corporation (now Standard BioTools)
- **2022-2024** — General Manager and Executive Vice President of Operations at InterVenn Biosciences
- **2024-present** — President and CEO at InterVenn Biosciences

## Achievements

- Led InterVenn Biosciences through its $201 million Series C fundraise in August 2021
- Oversaw development and commercialization of GlycoKnow Ovarian, a proprietary blood-based non-invasive ovarian cancer diagnostic
- Secured AMA PLA code for GlycoKnow Ovarian in 2025, enabling wider clinical integration
- Brokered partnership with Aranscia in 2026 to accelerate GlycoKnow commercialization
- Published extensively in cancer research; served on editorial boards of Cancer Research and The American Journal of Pathology
- Led computational biology and materials science groups at Lawrence Livermore National Laboratory
- Joined Fluidigm as CSO in 2019, expanding oncology and immunology research capabilities

## Latest updates

- **2026-01** — InterVenn Biosciences partnered with Aranscia to accelerate commercialization of GlycoKnow Ovarian non-invasive ovarian cancer diagnostic test
- **2025-07** — InterVenn received AMA PLA code for GlycoKnow Ovarian, enabling standardized access across the U.S. healthcare system
- **2025-03** — Andrew Quong appointed as Chief Executive Officer of InterVenn Biosciences, transitioning from EVP/GM role

## Links

- Website: https://intervenn.com
- LinkedIn: http://www.linkedin.com/in/andrew-quong-61211821
- Twitter/X: https://twitter.com/vennbio
- Facebook: https://facebook.com/intervenn/

---

Profile page: https://yespress.io/andrew-quong
Published by YesPress — https://yespress.io
Last updated: 2026-05-14